Galena Biopharma, Inc. (NASDAQ:GALE)

CAPS Rating: 1 out of 5

Results 1 - 11 of 11

Recs

0
Member Avatar chrispycrunch (80.83) Submitted: 5/19/2015 10:08:47 AM : Underperform Start Price: $2.71 GALE Score: +60.73

CLASSIC PUMP AND DUMP. This company will go to 0.

Recs

0
Member Avatar clangmead (36.44) Submitted: 5/18/2015 6:41:53 AM : Outperform Start Price: $1.34 GALE Score: -1.34

pweek

Recs

1
Member Avatar zzlangerhans (99.79) Submitted: 3/26/2015 12:01:07 AM : Outperform Start Price: $1.47 GALE Score: -10.88

There's something about cult stocks that have fallen out of favor that I find strangely attractive. I see them as dormant time bombs, awaiting some undefinable catalyst that will launch the cult back into active status. Of course, more often than not the crippled stock continues to sink as the market continues to ignore it. In the case of Galena, I'm hoping to see some life ooze back into the stock if the PRESENT phase III trial of NeuVax for low/intermediate HER2+ node positive breast cancer passes an interim analysis in early 2016. That's admittedly a long time to wait and biopharma is almost certainly due for rough seas at some point this year, so it's probably not a good time to put real money in Galena. Data from a phase IIb trial of NeuVax with Herceptin in node positive triple negative HER2 IHC 1+/2+ breast cancer is also expected in 2016. Galena is keeping the lights on with a 50M ATM with vulture financier Lincoln Park, which is another ongoing negative for current shareholders. The most positive thing about Galena is the possibility that the company has taken maximal damage from the pay for promotion scandal of 2014.

Recs

0
Member Avatar stemcells2011 (91.08) Submitted: 3/25/2015 12:31:39 AM : Outperform Start Price: $1.49 GALE Score: -12.86

2 thumbs up from zzporte! I wasn't sure which way to go thanks.

Recs

1
Member Avatar marsuculix (45.96) Submitted: 3/23/2015 8:53:28 AM : Outperform Start Price: $1.49 GALE Score: -12.20

Galena has delivered exciting results for its still clinical-stage cancer vaccine NeuVax: In phase 2 studies just 5.6% of patients receiving NeuVax had their cancer recur over a 60-month period, compared to 25.9% of patients in the control group.

Recs

1
Member Avatar ruinas (49.17) Submitted: 12/27/2014 3:50:21 PM : Underperform Start Price: $1.53 GALE Score: +15.61

Markets overbought - correction due

Recs

0
Member Avatar bargain123 (34.95) Submitted: 12/26/2014 5:46:04 PM : Outperform Start Price: $1.53 GALE Score: -15.61

Technicals look good, product matured, this company will either make money on its own or been bought by Big Guy in this space

Recs

0
Member Avatar DougD720 (< 20) Submitted: 7/17/2014 11:05:35 AM : Outperform Start Price: $2.65 GALE Score: -57.95

Neuvax, highly undervalued due to scandal, still solid company with an excellent pipeline.

Recs

0
Member Avatar herbertslojewski (65.16) Submitted: 7/7/2014 3:56:58 PM : Outperform Start Price: $2.94 GALE Score: -63.29

Great new anti-cancer developments.

Recs

0
Member Avatar manirg (86.48) Submitted: 3/11/2014 9:48:12 AM : Outperform Start Price: $3.37 GALE Score: -74.23

highly undervalued, huge potential, has 2 drugs approved

Recs

0
Member Avatar jgvega (< 20) Submitted: 2/23/2014 3:58:40 PM : Outperform Start Price: $3.92 GALE Score: -81.93

Great chances of being revenue positive towards the end of the year thanks to drug Abstral. Huge market potential for breast cancer drug NueVax (if passed by FDA. it has great chances). Positive ratings from many analysts. Oh, and it’s undervalued due to recently ended bear raid. All and all, great stock and price with multi bagger potential for 2014. check it out.

Results 1 - 11 of 11

Featured Broker Partners


Advertisement